Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk

DOI PDF 被引用文献1件
  • Fangcheng Yuan
    1Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
  • Rayjean J. Hung
    3Lunenfeld-Tanenbaum Research Institute, Sinai Health System and University of Toronto, Toronto, Ontario, Canada.
  • Naomi Walsh
    4National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, Ireland.
  • Han Zhang
    1Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
  • Elizabeth A. Platz
    2Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
  • William Wheeler
    6Information Management Services, Inc., Silver Spring, Maryland.
  • Lei Song
    1Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
  • Alan A. Arslan
    7Department of Obstetrics and Gynecology, New York University School of Medicine, New York, New York, USA.
  • Laura E. Beane Freeman
    1Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
  • Paige Bracci
    11Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.
  • Federico Canzian
    12Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Mengmeng Du
    13Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Steven Gallinger
    3Lunenfeld-Tanenbaum Research Institute, Sinai Health System and University of Toronto, Toronto, Ontario, Canada.
  • Graham G. Giles
    14Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.
  • Phyllis J. Goodman
    17SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Charles Kooperberg
    18Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Loic Le Marchand
    19Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii.
  • Rachel E. Neale
    20Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • Jonas Rosendahl
    21Department of Internal Medicine I, Martin Luther University, Halle, Germany.
  • Ghislaine Scelo
    22International Agency for Research on Cancer, Lyon, France.
  • Xiao-Ou Shu
    23Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
  • Kala Visvanathan
    2Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
  • Emily White
    24Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Wei Zheng
    23Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
  • Demetrius Albanes
    1Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
  • Pilar Amiano
    25Public Health Division of Gipuzkoa, Ministry of Health of the Basque Government, Donostia-San Sebastian, Spain.
  • Gabriella Andreotti
    1Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
  • Ana Babic
    28Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • William R. Bamlet
    29Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota.
  • Sonja I. Berndt
    1Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
  • Paul Brennan
    22International Agency for Research on Cancer, Lyon, France.
  • Bas Bueno-de-Mesquita
    30Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • Julie E. Buring
    34Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Peter T. Campbell
    36Behavioral and Epidemiology Research Group, American Cancer Society, Atlanta, Georgia.
  • Stephen J. Chanock
    1Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
  • Charles S. Fuchs
    37Yale Cancer Center, New Haven, Connecticut.
  • J. Michael Gaziano
    35Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Michael G. Goggins
    41Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins School of Medicine, Baltimore, Maryland.
  • Thilo Hackert
    42Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.
  • Patricia Hartge
    1Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
  • Manal M. Hassan
    43Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Elizabeth A. Holly
    11Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.
  • Robert N. Hoover
    1Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
  • Verena Katzke
    44Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Holger Kirsten
    45Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.
  • Robert C. Kurtz
    47Gastroenterology, Hepatology, and Nutrition Service, Memorial Sloan Kettering Cancer Center, New York, New York.
  • I-Min Lee
    34Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Nuria Malats
    48Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre, Madrid, Spain.
  • Roger L. Milne
    14Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.
  • Neil Murphy
    49Section of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France.
  • Kimmie Ng
    28Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Ann L. Oberg
    29Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota.
  • Miquel Porta
    50CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
  • Kari G. Rabe
    29Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota.
  • Francisco X. Real
    52CIBERONC, Madrid, Spain.
  • Nathaniel Rothman
    1Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
  • Howard D. Sesso
    34Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Debra T. Silverman
    1Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
  • Ian M. Thompson
    55CHRISTUS Santa Rosa Hospital – Medical Center, San Antonio, Texas.
  • Jean Wactawski-Wende
    56Department of Epidemiology and Environmental Health, University at Buffalo, Buffalo, New York.
  • Xiaoliang Wang
    24Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Nicolas Wentzensen
    1Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
  • Lynne R. Wilkens
    19Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii.
  • Herbert Yu
    19Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii.
  • Anne Zeleniuch-Jacquotte
    8Department of Population Health, New York University School of Medicine, New York, New York.
  • Jianxin Shi
    1Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
  • Eric J. Duell
    57Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Bellvitge Biomedical Research Institute (IDIBELL), Catalan Institute of Oncology (ICO), Barcelona, Spain.
  • Laufey T. Amundadottir
    1Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
  • Donghui Li
    43Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Gloria M. Petersen
    29Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota.
  • Brian M. Wolpin
    28Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Harvey A. Risch
    58Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut.
  • Kai Yu
    1Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
  • Alison P. Klein
    2Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
  • Rachael Stolzenberg-Solomon
    1Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.

抄録

<jats:title>Abstract</jats:title> <jats:sec> <jats:title /> <jats:p>Registry-based epidemiologic studies suggest associations between chronic inflammatory intestinal diseases and pancreatic ductal adenocarcinoma (PDAC). As genetic susceptibility contributes to a large proportion of chronic inflammatory intestinal diseases, we hypothesize that the genomic regions surrounding established genome-wide associated variants for these chronic inflammatory diseases are associated with PDAC. We examined the association between PDAC and genomic regions (±500 kb) surrounding established common susceptibility variants for ulcerative colitis, Crohn's disease, inflammatory bowel disease, celiac disease, chronic pancreatitis, and primary sclerosing cholangitis. We analyzed summary statistics from genome-wide association studies data for 8,384 cases and 11,955 controls of European descent from two large consortium studies using the summary data-based adaptive rank truncated product method to examine the overall association of combined genomic regions for each inflammatory disease group. Combined genomic susceptibility regions for ulcerative colitis, Crohn disease, inflammatory bowel disease, and chronic pancreatitis were associated with PDAC at P values &lt; 0.05 (0.0040, 0.0057, 0.011, and 3.4 × 10−6, respectively). After excluding the 20 PDAC susceptibility regions (±500 kb) previously identified by GWAS, the genomic regions for ulcerative colitis, Crohn disease, and inflammatory bowel disease remained associated with PDAC (P = 0.0029, 0.0057, and 0.0098, respectively). Genomic regions for celiac disease (P = 0.22) and primary sclerosing cholangitis (P = 0.078) were not associated with PDAC. Our results support the hypothesis that genomic regions surrounding variants associated with inflammatory intestinal diseases, particularly, ulcerative colitis, Crohn disease, inflammatory bowel disease, and chronic pancreatitis are associated with PDAC.</jats:p> </jats:sec> <jats:sec> <jats:title>Significance:</jats:title> <jats:p>The joint effects of common variants in genomic regions containing susceptibility loci for inflammatory bowel disease and chronic pancreatitis are associated with PDAC and may provide insights to understanding pancreatic cancer etiology.</jats:p> </jats:sec>

収録刊行物

  • Cancer Research

    Cancer Research 80 (18), 4004-4013, 2020-09-15

    American Association for Cancer Research (AACR)

被引用文献 (1)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ